Form 4: Regeneron Director Sells Shares Under 10b5-1 Plan

Regeneron Pharmaceuticals Director Arthur F. Ryan sold common stock totaling 90 shares on February 9, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Arthur F. Ryan, a Director of Regeneron Pharmaceuticals, Inc. (REGN), reported multiple sales of common stock.
• The transactions occurred on February 9, 2026.
• A total of 90 shares were disposed of across several transactions.
• The sales were executed pursuant to a Rule 10b5-1(c) trading plan adopted on October 31, 2025.
• Following these transactions, Arthur F. Ryan beneficially owns 17,803 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Insider sales under a pre-arranged 10b5-1 plan are routine and typically do not reflect a change in sentiment regarding the company's prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives and directors, often used for personal financial planning and diversification, and do not necessarily indicate a change in the company's fundamental outlook or the insider's confidence in the company.

Stakeholder Impact

• Shareholders: Minor dilution effect from the sale of shares, but the overall impact is negligible given the small number of shares relative to the total outstanding shares.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-arranged Rule 10b5-1 trading plan. Such sales are typically for personal financial planning and diversification and do not signal a change in the company's fundamentals or the insider's long-term view. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

Regeneron Pharmaceuticals, REGN, Arthur F. Ryan, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Biotechnology, Pharmaceuticals